Limited extranodal Hodgkin's disease

Unfavorable prognosis and therapeutic implications
      This paper is only available as a PDF. To read, Please Download here.


      The Ann Arbor Conference on the staging of Hodgkin's disease suggested that the prognosis in patients with “E” stage Hodgkin's disease is similar to that in comparable patients with only nodal disease. A comparative analysis was undertaken of 84 patients with pathologically staged IIA to IIIA disease and 18 patients with stage IIEA to IIIEA disease. The lung was the principal site of extranodal extension (15 patients). Both groups were treated concurrently with either extended field irradiation alone or limited field irradiation followed by MOPP chemotherapy (nitrogen mustard, vincristine, procarbazine and prednisone). Relapse rates after irradiation alone were 29 per cent for the patients with stage HA to IIIA disease and 82 per cent for the patients with “E” stage disease. Patients who received adjuvant chemotherapy had relapse rates of 6 per cent and 14 per cent, respectively. Most “E” stage relapses were regional recurrences within the lung parenchyma. Wilcoxon analysis revealed a significantly shorter remission duration and survival for the patients with “E” stage disease after irradiation alone, but there were no differences between the two patient populations treated with irradiation followed by chemotherapy. These data indicate that the prognosis in patients with “E” stage Hodgkin's disease of the lung is poor when they are treated with irradiation alone, and that adjuvant chemotherapy should be considered for such patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Carbone PP
        • Kaplan HS
        • Musshoff K
        • et al.
        Report of the committee on Hodgkin's disease staging classification.
        Cancer Res. 1971; 31: 1860
        • Musshoff K
        Prognostic and therapeutic implications of staging in extranodal Hodgkin,s disease.
        Cancer Res. 1971; 31: 1814
        • Peters MV
        • Hasselback R
        • Brown TC
        The natural history of the lymphomas related to the clinical classification.
        in: Zarafonetis CJD Proceedings of the International Conference on Leukemia-Lymphoma. Lea & Febiger, Philadelphia1968: 357
        • O'Connell MJ
        • Wiernik PH
        • Sklansky BD
        • et al.
        Staging laparotomy in Hodgkin's disease.
        Am J Med. 1974; 57: 86
        • Lukes RJ
        • Craver LF
        • Hall TC
        • et al.
        Report of the nomenclature committee.
        Cancer Res. 1966; 26: 1311
        • Brace K
        • Serpick AA
        • Block JB
        • et al.
        Combination radiotherapy and chemotherapy in the treatment of early Hodgkin's disease.
        Oncology. 1973; 27: 484
        • Kaplan HS
        Hodgkin's Disease.
        Harvard University Press, Cambridge, Mass1972
        • O'Connell MJ
        • Wiernik PH
        • Brace KC
        • et al.
        A combined modality approach to the treatment of Hodgkin's disease.
        Cancer. 1975; 35: 1055
        • Diggs CH
        • Wiernik PH
        • Levi JA
        • et al.
        Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin,s disease.
        Cancer. 1977; 39: 1949
        • Kaplan HS
        • Meier P
        Non-parametric estimations from incomplete observation.
        Am Stat Assoc J. 1958; 53: 457
        • Gehan EA
        A generalized Wilcoxon test for comparing arbitrarily singly-censored samples.
        Biometrika. 1965; 52: 203
        • Kaplan HS
        • Rosenberg SA
        Current status of clinical trials: Stanford experience, 1962–1972.
        Natl Cancer Inst Monogr. 1973; 36: 363
        • Johnson RE
        • Glover MK
        • Marshall SK
        Results of radiation therapy and implications for the clinical staging of Hodgkin:s disease.
        Cancer Res. 1971; 31: 1834
        • Hutchison GB
        Progress Report: Hodgkin's Clinical Trial, 1972.
        Natl Cancer Inst Monogr. 1973; 36: 387
        • Tubiana M
        The place of radiotherapy in the treatment of malignant lymphoma.
        Clin Haematol. 1974; 3: 161
        • Rosenberg SA
        • Kaplan HS
        The management of stages I, II, and III Hodgkin's disease with combined radiotherapy and chemotherapy.
        Cancer. 1975; 35: 55
        • Kaplan HS
        • Rosenberg SA
        The management of Hodgkins disease.
        Cancer. 1975; 36: 796
        • Kaplan HS
        Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease.
        Cancer Res. 1966; 26: 1221
        • Palos B
        • Kaplan HS
        • Karzmark CJ
        The use of thin lung shields to deliver limited whole-lung irradiation during mantle-field treatment of Hodgkin:s disease.
        Radiology. 1971; 101: 441